IDiyas

For the Inventor, By the Inventor

Cologne, Germany

Matthias Schramm

USPTO Granted Patents = 44

Average Co-Inventor Count = 5.5

ph-index = 7

Forward Citations = 291(Granted Patents)


Location History:

  • Koeln, DE (1988)
  • Cologne, DE (1985 - 1992)
  • Leverkusen, DE (1993 - 1999)

Company Filing History:

goldMedal44 out of 12,157 
 
Bayer Aktiengesellschaft
 patents

Years Active: 1985-1999

Loading Chart...
44 patents (USPTO):Explore Patents
1. 5866571 - 9-substituted 2-(2-n-alkoxyphenyl)-purin-6-ones (1999-02-02),
2. 5861404 - 2,9-disubstituted purin-6-ones (1999-01-19),
3. 5721238 - 2,8-disubstituted quinazolinones (1998-02-24),
4. 5420142 - Certain 3-formyl-1, 4-dihydropyridines and their pharmaceutical (1995-05-30),
5. 5344944 - Circulation-active dioxyalkylenearyl-dihydropyridines (1994-09-06),
6. 5272161 - Indolesulphonamide-substituted dihydropyridines (1993-12-21),
7. 5162338 - Circulation active 4-aminoaryldihydropryidine lactones (1992-11-10),
8. 5138091 - 1,4-dihydropyridine-threonine derivatives with cardiovascular activity (1992-08-11),
9. 5051433 - Pharmaceutically active basic nitro-phenyl-dihydropyridine amides (1991-09-24),
10. 5017590 - 1,4-dihydropyridine-threonine compounds with cardiovascular activity (1991-05-21),
11. 5015650 - Circulation-active basic 4-aryl-DHP amides (1991-05-14),
12. 5008279 - Circulation-active fluoromethoxyphenyl dihydropyridine compounds (1991-04-16),
13. 4904665 - Benzylaminoaryl-dihydropyridinelactones and their use in medicaments (1990-02-27),
14. 4898877 - Circulation-active cyclohexenecarboxylates (1990-02-06),
15. 4898865 - [4-(6-Oxo-1,4,5,6-tetrahydro-3-pyridazinyl) anilino hexyl (1990-02-06),

Title: Innovations in Medicinal Chemistry: The Contributions of Matthias Schramm

Introduction: Matthias Schramm is a prominent inventor based in Cologne, Germany, known for his significant contributions in the field of medicinal chemistry. With an impressive portfolio of 44 patents, Schramm's work focuses on the development of innovative compounds with potential therapeutic applications.

Latest Patents: Two of his latest patents include the development of 9-substituted 2-(2-n-alkoxyphenyl)-purin-6-ones and 2,9-disubstituted purin-6-ones. The former is synthesized by cyclizing appropriately substituted imidazoles and can be utilized in medicaments, particularly for treating inflammation, thromboembolic diseases, and cardiovascular issues. Meanwhile, the latter is prepared through acylation of substituted aminoimidazoles, leading to compounds that have therapeutic potentials for similar health conditions, as well as diseases pertaining to the urogenital system.

Career Highlights: Matthias Schramm is affiliated with Bayer Aktiengesellschaft, a leading global enterprise with a strong emphasis on healthcare and agriculture. His work within this reputable company showcases his commitment to innovation and the advancement of medical treatments through his inventive methodologies.

Collaborations: Schramm's journey in the world of inventions has been further enhanced by collaborations with notable colleagues, including Rainer Gross and Gerhard Franckowiak. These partnerships have likely facilitated the exchange of ideas and expertise, contributing to the successful development of his patented innovations.

Conclusion: Matthias Schramm's contributions not only highlight his individual brilliance as an inventor but also underscore the collaborative nature of innovation in medicinal chemistry. His latest patents represent strides toward effective treatments for various diseases, establishing him as a significant figure in contemporary pharmaceutical advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…